Pfizer Inc.
PFE Healthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.
Follow PFE
Pfizer Inc. (PFE) Revenue
Pfizer Inc.'s revenue for fiscal 2025 was $62.6B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $63.7B. Over the past ten years it has ranged from $40.8B (fiscal 2018) to $101.2B (fiscal 2022); the current reading is higher than 73% of that period. Pfizer Inc. ranks 5th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $62.6B | (1.65%) |
| FY2024 | $63.6B | 6.84% |
| FY2023 | $59.6B | (41.14%) |
| FY2022 | $101.2B | 24.46% |
| FY2021 | $81.3B | 95.16% |
| FY2020 | $41.7B | 1.82% |
| FY2019 | $40.9B | 0.20% |
| FY2018 | $40.8B | (22.31%) |
| FY2017 | $52.5B | (0.53%) |
| FY2016 | $52.8B | 8.13% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $15.0B | 4.03% |
| Mar 2026 | $14.5B | (17.69%) |
| Dec 2025 | $17.6B | 5.42% |
| Sep 2025 | $16.7B | 13.66% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| PFE Pfizer Inc. | $63.7B |
| AZN AstraZeneca PLC compare | $61.4B |
| SNY Sanofi compare | $57.0B |
| NVS Novartis AG compare | $56.7B |
| NVO Novo Nordisk A/S compare | $51.5B |
| BMY Bristol Myers Squibb Company compare | $49.2B |
| GSK GSK PLC Sponsored ADR compare | $44.5B |
| AMGN Amgen Inc. compare | $38.1B |
| GILD Gilead Sciences, Inc. compare | $30.5B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on PFE
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement